Get the Stockscreener App
6.91
0.58%
0.04
Kyntra Bio Inc stock is traded at $6.91, with a volume of 6,215.
It is up +0.58% in the last 24 hours and up +1.32% over the past month.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
See More
Previous Close:
$6.87
Open:
$7.045
24h Volume:
6,215
Relative Volume:
0.28
Market Cap:
$27.97M
Revenue:
$7.44M
Net Income/Loss:
$-56.57M
P/E Ratio:
0.2516
EPS:
27.467
Net Cash Flow:
$-21.40M
1W Performance:
+3.29%
1M Performance:
+1.32%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.83
$7.045
1-Week Range:
$6.61
$7.95
52-Week Range:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Name
Kyntra Bio Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
6.91 | 27.81M | 7.44M | -56.57M | -21.40M | 27.47 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
View All
Kyntra Bio Inc Stock (KYNB) Latest News
Kyntra Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineLong-Term Guidance - newsline.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Misses Expectations, Shares Rally on Pipeline Progress - newsline.com
Kyntra Bio (KYNB) Reveals Positive Trial Results for Anemia Trea - GuruFocus
Kyntra Bio stock rises on roxadustat MDS trial data - Investing.com
Kyntra Bio stock rises on roxadustat MDS trial data By Investing.com - Investing.com Australia
Kyntra Bio presents roxadustat data for anemia in LR-MDS patients By Investing.com - Investing.com Australia
Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes - TradingView
Kyntra Bio presents roxadustat data for anemia in LR-MDS patients - Investing.com
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes - The Manila Times
Kyntra Bio Presents New Roxadustat Data on Improvements in - GlobeNewswire
Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca - Moomoo
Kyntra Bio Receives Final Payment for China Divestiture - TipRanks
Kyntra Bio (KYNB) CEO updates holdings after RSU tax-withholding event - Stock Titan
[Form 4] KYNTRA BIO, INC. Insider Trading Activity - Stock Titan
Kyntra Bio receives final $4.0M holdback from AstraZeneca, completes China sale proceeds - TradingView
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
KYNB Initiated by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Kyntra Bio stock with buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates Kyntra Bio stock with buy rating - Investing.com
Kyntra Bio Inc. (KYNB) Faces Selling Pressure as Stock Dips 1.47% – Key Levels in FocusFloat Adjusted Cap - newsline.com
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio Inc. Q1 2026 Earnings: EPS Miss Amid Ongoing Pre-Revenue Development PhaseEarnings Manipulation Risk - newsline.com
Kyntra Bio Inc. Q1 2026 Earnings: Wider-Than-Expected Loss Reinforces Pre-Revenue ChallengesHigh Growth Earnings - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue R&D Push - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor SentimentProfit Margin Analysis - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges HigherEPS Growth Rate - The Legal Advocate
KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio CEO Thane Wettig buys $19,852 in stock - Investing.com India
Kyntra Bio CEO Thane Wettig buys $19,852 in stock By Investing.com - Investing.com Canada
KYNTRA BIO (KYNB) CEO Thane Wettig adds 2,800 shares in open-market buy - Stock Titan
What's Next for Kyntra Bio (KYNB) at $6.80? 2026-05-19Growth Picks - Newser
Kyntra Bio Rocked by CEO’s Sudden Insider Stock Sale - TipRanks
Kyntra Bio CEO Thane Wettig buys $19,852 in company stock By Investing.com - Investing.com Australia
Kyntra Bio CEO Thane Wettig buys $19,852 in company stock - Investing.com India
KYNTRA BIO (KYNB) CEO Thane Wettig purchases 2,800 shares at $7.09 - Stock Titan
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript - AOL.com
Armistice Capital (FGEN) reports 400,000-share, 9.88% position (May 2026) - Stock Titan
Kyntra Bio (KYNB) Institutional Ownership 2026 - MarketBeat
Number of shareholders of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
Number of shareholders of Kyntra Bio, Inc. – LSE:0IL8 - TradingView
Kyntra Bio (Nasdaq: KYNB) Q1 2026 results show higher revenue, ongoing R&D spend - Stock Titan
Kyntra Bio stock (US3156631046): Q1 2026 revenue rises to $3.7M amid pipeline advances - AD HOC NEWS
Kyntra Bio Inc. (KYNB) News, Articles, Events & Latest Updates - Stocktwits
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances Amidst Challenges - GuruFocus
Kyntra Bio targets Q4 2026 interim readout while extending cash runway into 2028 - MSN
Kyntra Bio Inc Stock (KYNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kyntra Bio Inc Stock (KYNB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):